Document is current
Any future updates will be listed below
-
Authors
Kortekaas, Kim E
Santegoets, Saskia J https://orcid.org/0000-0002-2874-4402
Tas, Liselotte
Ehsan, Ilina
Charoentong, Pornpimol
van Doorn, Helena C
van Poelgeest, Mariette I E
Mustafa, Dana A M
van der Burg, Sjoerd H https://orcid.org/0000-0002-6556-0354
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02794571 at ClinicalTrials.govnct02913313 at ClinicalTrials.govDocuments that mention this clinical trial
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study
https://doi.org/10.1136/bmjopen-2024-096617
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors
https://doi.org/10.1136/bmjonc-2025-001037
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
https://doi.org/10.1136/jitc-2021-003671
nct03628677 at ClinicalTrials.govDocuments that mention this clinical trial
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
https://doi.org/10.1136/jitc-2021-003671
Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)
https://doi.org/10.1136/jclinpath-2021-207789
nct04669899 at ClinicalTrials.govDocuments that mention this clinical trial
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
https://doi.org/10.1136/jitc-2021-003671
Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)
https://doi.org/10.1136/jclinpath-2021-207789
475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells
https://doi.org/10.1136/jitc-2023-sitc2023.0475
Documents that mention this clinical trial
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.4531
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
https://doi.org/10.1136/jitc-2021-003671
-
Funding
Funding for this research was provided by:
Dutch Cancer Society (2016-10168)
- License Information
